Eloxx Pharmaceuticals, Inc.
(NASDAQ : ELOX)

( )
ELOX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
VTLVital Therapies, Inc.
1.50%13.513.3%$792.68m
AMGNAmgen Inc.
0.97%206.001.3%$773.44m
GILDGilead Sciences, Inc.
1.54%64.110.9%$388.34m
CELGCelgene Corporation
0.51%95.221.3%$348.72m
BIIBBiogen Inc.
1.74%235.721.3%$309.32m
ILMNIllumina, Inc.
0.87%288.653.5%$303.84m
VRTXVertex Pharmaceuticals Incorporated
1.16%187.091.9%$267.03m
ALXNAlexion Pharmaceuticals, Inc.
1.65%112.682.0%$250.97m
EXASExact Sciences Corporation
-1.39%118.1624.1%$248.01m
REGNRegeneron Pharmaceuticals, Inc.
0.52%298.382.6%$217.05m
AAgilent Technologies, Inc.
0.96%71.761.6%$206.55m
SRPTSarepta Therapeutics, Inc.
-3.71%120.3114.7%$153.85m
INCYIncyte Corporation
1.68%84.522.5%$100.26m
BMRNBioMarin Pharmaceutical Inc.
1.19%77.414.3%$94.71m
GHDXGenomic Health, Inc.
-0.56%74.221.8%$90.42m

Company Profile

Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. It operates through the United States and Israel geographical segments. Its product includes ELX-02, a small molecule drug designed to restore production of full-length functional proteins which treats cystic fibrosis and cystinosis. The company was founded on December 19, 2017 and is headquartered in Waltham, MA.